Lovell, Katie K.
Momin, Rushan I.
Sangha, Harneet Singh
Feldman, Steven R.
Pichardo, Rita O.
Funding for this research was provided by:
Wake Forest University
Article History
Accepted: 2 July 2024
First Online: 30 July 2024
Declarations
:
: None.
: S.R. Feldman has received research, speaking and/or consulting support from Eli Lilly and Company, GlaxoSmithKline/Stiefel, AbbVie, Janssen, Alovtech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Boehringer Ingelheim, Amgen, Dermavant, Arcutis, Novartis, Novan, UCB, Helsinn, Sun Pharma, Almirall, Galderma, Leo Pharma, Mylan, Celgene, Ortho Dermatology, Menlo, Merck & Co, Qurient, Forte, Arena, Biocon, Accordant, Argenx, Sanofi, Regeneron, the National Biological Corporation, Caremark, Teladoc, BMS, Ono, Micreos, Eurofins, Informa, UpToDate, and the National Psoriasis Foundation. He is founder and part owner of Causa Research and holds stock in Sensal Health. K.K. Lovell, R.I. Momin, H. S. Sangha, and R. O. Pichardo have no conflicts of interest to disclose.
: Katie K. Lovell: conceptualization, investigation, writing—original draft, writing—review and editing, project administration. Rushan I. Momin: investigation, writing—original draft, writing—review and editing. Harneet Singh Sangha: investigation, writing—original draft, writing—review and editing. Steven R. Feldman: supervision, project administration, writing—review and editing. Rita O. Pichardo: conceptualization, supervision, project administration, writing—review and editing.
: Not applicable.
: Not applicable.
: Not applicable.